- Celtrix' SomatoKine (IGF-BP3) can deliver insulin-like growth factor-1 at much higher doses than previously possible, according to the results of an initial Phase I study. SomatoKine combines IGF with its major binding protein, BP3. Most naturally-occurring IGF-1 circulates in the body in this complexed form. The firm intends to study SomatoKine's effects as a hormone replacement in critically-ill patients, such as those undergoing major surgery, or with organ damage/failure and trauma, in a Phase II study later this fiscal year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze